Aripiprazole: A treatment for severe coprolalia in “refractory” Gilles de la Tourette syndrome
Identifieur interne : 003502 ( Istex/Curation ); précédent : 003501; suivant : 003503Aripiprazole: A treatment for severe coprolalia in “refractory” Gilles de la Tourette syndrome
Auteurs : Mouna Ben Djebara [France] ; Yulia Worbe [France] ; Michael Schüpbach [France] ; Andreas Hartmann [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-02-15.
English descriptors
Abstract
Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28‐year‐old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21859
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003502
Links to Exploration step
ISTEX:0D9D91ED59AA4281F9AEE5B48EF0248C77CB833ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Aripiprazole: A treatment for severe coprolalia in “refractory” Gilles de la Tourette syndrome</title>
<author><name sortKey="Ben Djebara, Mouna" sort="Ben Djebara, Mouna" uniqKey="Ben Djebara M" first="Mouna" last="Ben Djebara">Mouna Ben Djebara</name>
<affiliation wicri:level="1"><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre d'Investigation Clinique, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Faculté de Médecine, Université Pierre et Marie Curie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Faculté de Médecine, Université Pierre et Marie Curie, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Worbe, Yulia" sort="Worbe, Yulia" uniqKey="Worbe Y" first="Yulia" last="Worbe">Yulia Worbe</name>
<affiliation wicri:level="1"><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre d'Investigation Clinique, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Faculté de Médecine, Université Pierre et Marie Curie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Faculté de Médecine, Université Pierre et Marie Curie, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Schupbach, Michael" sort="Schupbach, Michael" uniqKey="Schupbach M" first="Michael" last="Schüpbach">Michael Schüpbach</name>
<affiliation wicri:level="1"><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre d'Investigation Clinique, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Faculté de Médecine, Université Pierre et Marie Curie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Faculté de Médecine, Université Pierre et Marie Curie, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hartmann, Andreas" sort="Hartmann, Andreas" uniqKey="Hartmann A" first="Andreas" last="Hartmann">Andreas Hartmann</name>
<affiliation wicri:level="1"><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre d'Investigation Clinique, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Faculté de Médecine, Université Pierre et Marie Curie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Faculté de Médecine, Université Pierre et Marie Curie, Paris</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:0D9D91ED59AA4281F9AEE5B48EF0248C77CB833A</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.21859</idno>
<idno type="url">https://api.istex.fr/document/0D9D91ED59AA4281F9AEE5B48EF0248C77CB833A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003502</idno>
<idno type="wicri:Area/Istex/Curation">003502</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Aripiprazole: A treatment for severe coprolalia in “refractory” Gilles de la Tourette syndrome</title>
<author><name sortKey="Ben Djebara, Mouna" sort="Ben Djebara, Mouna" uniqKey="Ben Djebara M" first="Mouna" last="Ben Djebara">Mouna Ben Djebara</name>
<affiliation wicri:level="1"><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre d'Investigation Clinique, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Faculté de Médecine, Université Pierre et Marie Curie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Faculté de Médecine, Université Pierre et Marie Curie, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Worbe, Yulia" sort="Worbe, Yulia" uniqKey="Worbe Y" first="Yulia" last="Worbe">Yulia Worbe</name>
<affiliation wicri:level="1"><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre d'Investigation Clinique, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Faculté de Médecine, Université Pierre et Marie Curie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Faculté de Médecine, Université Pierre et Marie Curie, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Schupbach, Michael" sort="Schupbach, Michael" uniqKey="Schupbach M" first="Michael" last="Schüpbach">Michael Schüpbach</name>
<affiliation wicri:level="1"><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre d'Investigation Clinique, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Faculté de Médecine, Université Pierre et Marie Curie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Faculté de Médecine, Université Pierre et Marie Curie, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hartmann, Andreas" sort="Hartmann, Andreas" uniqKey="Hartmann A" first="Andreas" last="Hartmann">Andreas Hartmann</name>
<affiliation wicri:level="1"><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre d'Investigation Clinique, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>AP‐HP, Pitié‐Salpêtrière Group, Fédération de Neurologie, Paris</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Faculté de Médecine, Université Pierre et Marie Curie, Paris, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Faculté de Médecine, Université Pierre et Marie Curie, Paris</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-02-15">2008-02-15</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="438">438</biblScope>
<biblScope unit="page" to="440">440</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">0D9D91ED59AA4281F9AEE5B48EF0248C77CB833A</idno>
<idno type="DOI">10.1002/mds.21859</idno>
<idno type="ArticleID">MDS21859</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Gilles de la Tourette syndrome</term>
<term>aripiprazole</term>
<term>coprolalia</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28‐year‐old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics. © 2007 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003502 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 003502 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:0D9D91ED59AA4281F9AEE5B48EF0248C77CB833A |texte= Aripiprazole: A treatment for severe coprolalia in “refractory” Gilles de la Tourette syndrome }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |